Drug Research, Table of Contents Drug Res (Stuttg) 2021; 71(S 01): S5-S6DOI: 10.1055/a-1606-5387 Extended Abstract Gastrointestinale Erkrankungen: Forschungsschwerpunkte der Pharmafirmen Björn Fritz Recommend Article Abstract Full Text References Literatur 1 The hunt for a vaccine for hepatitis C virus continues. Lancet Gastroenterol Hepatol 2021; 6: 253 2 Institut des Bewertungsausschusses. Beschluss des Bewertungsausschusses nach § 87 Abs. 1 Satz 1 SGB V in seiner 567. Sitzung am 04.08.2021. Im Internet (Stand: 05.10.2021): https://institut-ba.de/ba/babeschluesse/2021-08-04_ba567_6.pdf 3 Sabino J, Verstockt B, Vermeire S. et al. New biologics and small molecules in inflammatory bowel disease: an update. Therap Adv Gastroenterol 2019; 12: 1756284819853208 4 Feagan BG, Danese S, Loftus Jr. E. et al. Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial. Lancet 2021; 397: 2372-2384 5 Im Internet (Stand: 05.10.2021): https://news.abbvie.com/news/press-releases/second-phase-3-induction-study-confirms-upadacitinib-rinvoq-improved-clinical-endoscopic-and-histologic-outcomes-in-ulcerative-colitis-patients.htm 6 Peyrin-Biroulet L, Sandborn W, Sands BE. et al. Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target. Am J Gastroenterol 2015; 110: 1324-1338 7 Turner D, Ricciuto A, Lewis A. et al. STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology 2021; 160: 1570-1583 8 Christensen B, Erlich J, Gibson PR. et al. Histologic healing is more strongly associated with clinical outcomes in ileal Crohnʼs disease than endoscopic healing. Clinical Gastroenter Hepatol 2020; 18: 2518-2525 9 Im Internet: https://news.abbvie.com/news/press-releases/second-phase-3-induction-study-confirms-upadacitinib-rinvoq-improved-clinical-endoscopic-and-histologic-outcomes-in-ulcerative-colitis-patients.htm 10 Im Internet: https://news.abbvie.com/alert-topics/immunology/upadacitinib-rinvoq-meets-primary-and-all-ranked-secondary-endpoints-in-first-phase-3-induction-study-in-ulcerative-colitis.htm 11 Im Internet: https://news.abbvie.com/news/press-releases/upadacitinib-rinvoq-met-primary-and-all-secondary-endpoints-in-52-week-phase-3-maintenance-study-in-ulcerative-colitis-patients.htm
